IL6ST and cancer: As previously mentioned, efforts to develop agents to block gp130/IL6ST in cancer will benefit from a better understanding of the signalling machinery, including the structure of cytokines and receptors and the specific residues involved in the recognition of protein partners and triggering of distinct downstream effects [324].